[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369099-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369099-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","validation-of-polymorphic-gompertzian-model-of-cancer-through-in-vitro-and-in-vivo-data-research-article","Validation of polymorphic Gompertzian model of cancer through in vitro and in vivo data - research article","","Mathematical modeling supports understanding and targeting therapy resistance mechanisms in cancer. This study evaluates the polymorphic Gompertzian model, which represents a heterogeneous tumor population containing therapy-sensitive and therapy-resistant cells. Results show the model captures trends in nonsmall cell lung cancer (NSCLC) dynamics under treatment across both in vitro and in vivo settings. For patient tumor dynamics, model comparison demonstrates improved goodness of fit and successful reproduction of the U-shaped tumor-size relapse pattern.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/validation-of-polymorphic-gompertzian-model-of-cancer-through-in-vitro-and-in-vivo-data-research-article/369099/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/validation-of-polymorphic-gompertzian-model-of-cancer-through-in-vitro-and-in-vivo-data-research-article/369099.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the polymorphic Gompertzian model represent in cancer?","Question",{"text":63,"@type":64},"It describes a heterogeneous cancer population consisting of therapy-sensitive and therapy-resistant cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the study validate the model?",{"text":68,"@type":64},"It tests agreement with both in vitro data and in vivo patient data on nonsmall cell lung cancer (NSCLC) dynamics under treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"What distinctive tumor-size behavior does the model capture?",{"text":72,"@type":64},"It successfully captures a U-shaped trend in tumor size during cancer relapse, which classical oncologic models cannot fit.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369099,1790409942,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","PLOS ONE  \nOPEN ACCESS  \nCitation: Soboleva A, Kaznatcheev A, Cavill R, Schneider K, Staňkov´a K (2025) Validation of polymorphic Gompertzian model of cancer through in vitro and in vivo data. PLoS ONE 20(1):  \ne0310844 . [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0310844  \nEditor: Julio Cesar de Souza, Universidade Federal  \nde Mato Grosso do Sul, BRAZIL Received: September 18, 2023  \nAccepted: September 6, 2024  \nPublished: January 9, 2025  \nCopyright: © 2025 Soboleva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: The in vitro data is available in Artem Kaznatcheev’s GitHub at [https://](https://)[ ](https://)[github.com/kaznatcheev/GameAssay](github.com/kaznatcheev/GameAssay. The)[. The](github.com/kaznatcheev/GameAssay. The) in vivo data is published as supplementary of Ghafari Laleh’s et al. paper ([https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pcbi.1009822.s006) .  \nFunding: This research was funded by H2020 Marie Sklodowska-Curie Actions ([https://marie](https://marie)[sklodowska-curie-actions.ec.europa.eu/](sklodowska-curie-actions.ec.europa.eu/)) (Award number 955708 [KS]) and Nederlandse Organisatie voor Wetenschappelijk Onderzoek ([https://www](https://www).  \nRESEARCH ARTICLE  \nValidation of polymorphic Gompertzian model of cancer through in vitro and in vivo data  \nArina Soboleva1 *, Artem Kaznatcheev2, Rachel Cavill3, Katharina Schneider3, Kateřina Staňkov´a1  \n1 Institute for Health Systems Science, Faculty of Technology, Policy and Management, Delft University of Technology, Delft, The Netherlands, 2 Department of Mathematics and Department of Information and Computing Sciences, Utrecht University, Utrecht, The Netherlands, 3 Department of Advanced Computing Sciences, Faculty of Science and Engineering, Maastricht University, Maastricht, The Netherlands  \n* [a.soboleva@tudelft.nl](a.soboleva@tudelft.nl)  \nAbstract  \nMathematical modeling plays an important role in our understanding and targeting therapy resistance mechanisms in cancer. The polymorphic Gompertzian model, analyzed theoretically and numerically by Viossat and Noble to demonstrate the benefits of adaptive therapy in metastatic cancer, describes a heterogeneous cancer population consisting of therapysensitive and therapy-resistant cells. In this study, we demonstrate that the polymorphic Gompertzian model successfully captures trends in both in vitro and in vivo data on nonsmall cell lung cancer (NSCLC) dynamics under treatment. Additionally, for the in vivo data of tumor dynamics in patients undergoing treatment, we compare the goodness of fit of the polymorphic Gompertzian model to that of the classical oncologic models, which were previously identified as the models that fit this data best. We show that the polymorphic Gompertzian model can successfully capture the U-shape trend in tumor size during cancer relapse, which can not be fitted with the classical oncologic models. In general, the polymorphic Gompertzian model corresponds well to both in vitro and in vivo real-world data, suggesting it as a candidate for improving the efficacy of cancer therapy, for example, through evolutionary/adaptive therapies.  \nIntroduction  \nFor patients with advanced cancer, an aggressive treatment aiming at complete cancer eradication is often ineffective [ 1–3] . Instead of pursuing tumor elimination through maximum tolerable dose (MTD), novel therapies, called evolutionary or adaptive therapies, aim to anticipate and steer cancer eco–evolutionary dynamics to maximize patients’ quality and quantity of life [3–18] . Mathematical models of cancer’s response to therapy may help us to improve therapies and, perhaps even more importantly, are needed to understand conditions under which the ev","cbCaihJLlWkW6og4","https://ap.wps.com/l/cbCaihJLlWkW6og4","pdf",2631396,13,"English","# Abstract\n# Introduction\n# Background and motivation\n## Limitations of standard treatment and rationale for adaptive therapy\n## Prior work on density-dependent polymorphic models and Gompertzian models\n# Model evaluation with real-world data","[{\"question\":\"What does the polymorphic Gompertzian model represent in cancer?\",\"answer\":\"It describes a heterogeneous cancer population consisting of therapy-sensitive and therapy-resistant cells.\"},{\"question\":\"How does the study validate the model?\",\"answer\":\"It tests agreement with both in vitro data and in vivo patient data on nonsmall cell lung cancer (NSCLC) dynamics under treatment.\"},{\"question\":\"What distinctive tumor-size behavior does the model capture?\",\"answer\":\"It successfully captures a U-shaped trend in tumor size during cancer relapse, which classical oncologic models cannot fit.\"}]","Validation of polymorphic Gompertzian model of cancer through in vitro and in vivo data - research article | PDF",1790180729,33,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/189671d7a9530aa462281490e5e69735.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3c59226fcc48ed98167a52394b09efb.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4a5a19adc62640a699df5cc44df3335.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f89fe232ade4e457084357d8e816343.webp",980,1268]